Applied Molecular Transport Inc. Stock: price and management transactions · United States · SEC (Form 4)

About Applied Molecular Transport Inc.

Applied Molecular Transport Inc. (AMTI) is a U.S.-listed biopharmaceutical company that has traded on the NASDAQ market in the United States. For French, Belgian and Swiss investors, AMTI should be viewed as a clinical-stage biotech rather than a revenue-generating pharmaceutical business. Its value proposition has historically been tied to proprietary science, intellectual property, and clinical milestones, all of which make the name highly sensitive to trial outcomes, financing needs, and corporate transactions. The company was incorporated in Delaware in November 2016 and its historic headquarters were in South San Francisco, California, placing it in one of the most established biotech clusters in the United States. According to SEC filings, AMTI spent much of its corporate life focused on research and development of a proprietary platform designed to create novel biologic drug candidates in patient-friendly oral dosage forms. In practical terms, the objective was to address a long-standing limitation in biologics: many effective biologic therapies must be injected, while AMTI aimed to enable oral delivery for certain protein-based medicines. From a business-line perspective, AMTI was not a diversified healthcare company. It was centered on a small pipeline and on platform technology. The company’s research emphasis covered autoimmune, inflammatory, metabolic and related diseases. Its lead program, AMT-101, was presented as the most advanced candidate, and the company stated in SEC disclosures that it had completed multiple Phase 2 clinical trials for that asset. That clinical-stage positioning offered upside if the platform proved successful, but it also exposed shareholders to binary development risk, regulatory uncertainty, and the need for continuing capital. In competitive terms, AMTI operated in a crowded biotech arena where it faced large established pharmaceutical companies, specialty biotech peers, and emerging platform-driven developers pursuing differentiated delivery technologies. The main competitive question was whether the company’s oral biologic platform could produce clinically meaningful and commercially viable products that would stand out from injectable biologics and other oral small-molecule alternatives. Recent corporate developments have been especially important. SEC disclosures show that AMTI discontinued certain research activities and began exploring strategic alternatives. In September 2023, the company announced a merger agreement with Cyclo Therapeutics, indicating a significant strategic pivot rather than a straightforward continuation of standalone development. Earlier filings also referenced Nasdaq listing concerns and the possibility of delisting, underlining that AMTI’s equity story has been shaped not only by science but also by capital structure and exchange-status issues. Overall, AMTI has evolved from a development-stage oral biologics story into a restructuring and strategic-transaction situation. For investors, the key takeaway is that any assessment of the company must weigh the scientific platform potential against the more recent realities of halted or reduced R&D activity, strategic alternatives, and the implications of NASDAQ market status in the United States.